Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-analysis

He, Dan; Lu, Weiping; Chang, Kai; Liu, Yueliang; Zhang, Jun; Zeng, Zhaofang

doi:10.1016/j.gene.2013.01.021

Cited by 6 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two functional SNPs (-2578C/A and -1154G/A) located in the promoter region of VEGF have been suggested to influence AD risk, but the results in this area are ambiguous. Previous metaanalysis has suggested that the AA genotype of -2578C/A is a risk factor for AD development in Europeans [95], but further studies with larger sample sizes seem to have negated this association [32,96]. However, in the subgroup of APOE e4 non-carriers, -2578C/A increases AD risk while -1154G/A plays a protective role [32].…”

Section: Other Pro-inflammatory Cytokinesmentioning

confidence: 96%

Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms

2016

View full text Add to dashboard Cite

Neuroinflammatory processes are a central feature of Alzheimer's disease (AD) in which microglia are over-activated, resulting in the increased production of proinflammatory cytokines. Moreover, deficiencies in the antiinflammatory system may also contribute to neuroinflammation. Recently, advanced methods for the analysis of genetic polymorphisms have further supported the relationship between neuroinflammatory factors and AD risk because a series of polymorphisms in inflammation-related genes have been shown to be associated with AD. In this review, we summarize the polymorphisms of both pro-and anti-inflammatory cytokines related to AD, primarily interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha, IL-4, IL-10, and transforming growth factor beta, as well as their functional activity in AD pathology. Exploration of the relationship between inflammatory cytokine polymorphisms and AD risk may facilitate our understanding of AD pathogenesis and contribute to improved treatment strategies.

show abstract

Section: Other Pro-inflammatory Cytokinesmentioning

confidence: 96%

Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms

2016

View full text Add to dashboard Cite

show abstract

“…141,142 The same platform has also been used by miRagen Therapeutic in the development of three drugs including MGN-9103 (targeting miR-208), MGN-1374 (targeting miR-15 and miR-195), and MGN-4893 (targeting miR-451). 143 These drugs are being developed in collaboration with Santaris Pharma A/S and are still at the preclinical stage. Chemical modification has also been widely used for siRNAs.…”

Section: Delivery Strategies For Mirna Therapeuticsmentioning

confidence: 99%

“…The chemical modifications in miravirsen can provide nuclease resistance and enhance its affinity to its target. Miravirsen is the first miRNA targeting drug that enters clinical trials and is currently in phase 2 trials for treating patients with HCV. , The same platform has also been used by miRagen Therapeutic in the development of three drugs including MGN-9103 (targeting miR-208), MGN-1374 (targeting miR-15 and miR-195), and MGN-4893 (targeting miR-451) . These drugs are being developed in collaboration with Santaris Pharma A/S and are still at the preclinical stage.…”

Section: Delivery Strategies For Mirna Therapeuticsmentioning

confidence: 99%

MicroRNAs and Drug Resistance in Prostate Cancers

Mahato

2014

Mol. Pharmaceutics

View full text Add to dashboard Cite

Prostate cancer is the second leading cause of cancer related death in American men. Androgen deprivation therapy (ADT) is used to treat patients with aggressive prostate cancers. After androgen deprivation therapy, prostate cancers slowly progress to an androgen-independent status. Taxanes (e.g., docetaxel) are used as standard treatments for androgen-independent prostate cancers. However, these chemotherapeutic agents will eventually become ineffective due to the development of drug resistance. A microRNA (miRNA) is a small noncoding RNA molecule, which can regulate gene expression at the post-transcription level. miRNAs elicit their effects by binding to the 3′-untranslated region (3′-UTR) of their target mRNAs, leading to the inhibition of translation or the degradation of the mRNAs. miRNAs have received increasing attention as targets for cancer therapy, as they can target multiple signaling pathways related to tumor progression, metastasis, invasion, and chemoresistance. Emerging evidence suggests that aberrant expression of miRNAs can lead to the development of resistant prostate cancers. Here, we discuss the roles of miRNAs in the development of resistant prostate cancers and their involvement in various drug resistant mechanisms including androgen signaling, apoptosis avoidance, multiple drug resistance (MDR) transporters, epithelialmesenchymal transition (EMT), and cancer stem cells (CSCs). In addition, we also discuss strategies for treating resistant prostate cancers by targeting specific miRNAs. Different delivery strategies are also discussed with focus on those that have been successfully used in human clinical trials.

show abstract

“…Additionally, high levels of VEGF have been found in cerebrospinal fluid (CSF) of patients with VaD 19 . A few studies have investigated the association between the VEGF gene (6p21.3) and AD with inconsistent results; whereas the haplotype GTC at G-1154A, G-7A, and C13553T of the VEGF gene has been associated with VaD in Koreans 20 , 21 .…”

Section: Introductionmentioning

confidence: 99%

Analysis of endothelial gene polymorphisms in Spanish patients with vascular dementia and Alzheimer´s disease

Manso-Calderón,

Cacabelos-Pérez,

Sevillano-García

et al. 2023

Sci Rep

View full text Add to dashboard Cite

There is increasing evidence for the involvement of blood–brain barrier (BBB) in vascular dementia (VaD) and Alzheimer´s disease (AD) pathogenesis. However, the role of endothelial function-related genes in these disorders remains unclear. We evaluated the association of four single-nucleotide polymorphisms (VEGF, VEGFR2 and NOS3) with diagnosis and rate of cognitive decline in AD and VaD in a Spanish case–control cohort (150 VaD, 147 AD and 150 controls). Participants carrying -604AA genotype in VEGFR2 (rs2071559) were less susceptible to VaD after multiple testing. Further analysis for VaD subtype revealed a significant difference between small-vessel VaD patients and controls, but not for large-vessel VaD patients. In addition, -2578A and -460C alleles in VEGF (rs699947 and rs833061) showed to decrease the risk of AD, whereas NOS3 (rs1799983) influenced disease progression. Our study supports previous findings of a deleterious effect of VEGFR2 reduced expression on small-vessel disease, but not on large-vessel disease; as well as a detrimental effect of down-regulating VEGF and eNOS in AD, affecting vascular permeability and neuronal survival. These data highlight the relevance of endothelial function and, therefore, BBB in both VaD and AD.

show abstract

Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-analysis

Cited by 6 publications

References 38 publications

Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms

Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms

MicroRNAs and Drug Resistance in Prostate Cancers

Analysis of endothelial gene polymorphisms in Spanish patients with vascular dementia and Alzheimer´s disease

Contact Info

Product

Resources

About